The multiple myeloma condition center is a comprehensive resource for clinical news and expert insights on multiple myeloma. Read more at OncLive.
May 16th 2024
Muhamed Baljevic, MD, discusses key trial updates and advancements with quadruplet therapy in newly diagnosed multiple myeloma.
Sundar Jagannath, MBBS, discusses takeaways from the FDA’s ODAC consensus on safety considerations with cilta-cel in relapsed/refractory multiple myeloma.
May 14th 2024
Sundar Jagannath, MBBS, discusses the safety of linvoseltamab in relapsed/refractory multiple myeloma.
In case you missed it, below is your guide to the important regulatory approvals made by the FDA in April 2024.
James Ignatz-Hoover, MD, PhD discusses sequencing CAR T cell therapies and bispecific agents in treating pretreated patients with multiple myeloma.
May 13th 2024
In case you missed any, below is a recap of every episode of OncLive On Air that aired in April 2024.
Following the consensus that the risk-benefit assessments for the proposed indications for cilta-cel and ide-cel were favorable during the March 15, 2024, FDA ODAC meeting, both BCMA-targeted CAR T-cell therapies received approvals moving them up in the treatment paradigm for relapsed or refractory multiple myeloma.
May 10th 2024
Sundar Jagannath, MBBS, discusses CAR T-cell therapy considerations prior to initiation in the management of multiple myeloma.
May 9th 2024
James Ignatz-Hoover, MD, PhD, discusses the current arsenal of FDA-approved bispecific antibodies in multiple myeloma.
May 8th 2024
Joseph G. Jurcic, MD, discusses the evolution of combination therapies in the management of myelofibrosis.
May 7th 2024
Krina K. Patel, MD, MSc, discusses her thoughts on moving CAR T-cell therapy up in the lines of treatment for patients with multiple myeloma.
May 6th 2024
Minoo Battiwalla, MD, discusses recent advancements in the multiple myeloma treatment paradigm.
Leland Metheny, MD, discusses how agents such as Iomab-B have potential to shift practice in the hematologic malignancy space.
May 3rd 2024
Sundar Jagannath, MBBS, discusses the patient population evaluated in the LINKER-MM1 trial of linvoseltamab in relapsed/refractory multiple myeloma.
The CAR T-cell therapy NXC-201 has received orphan drug designation from the European Commission for patients with multiple myeloma.
May 2nd 2024
Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.
April 29th 2024
Kenneth C. Anderson, MD, discusses the recent FDA ODAC decision regarding the use of cilta-cel in relapsed/refractory multiple myeloma.
April 25th 2024
Sundar Jagannath, MBBS, discusses linvoseltamab and expands on key efficacy and safety findings from the LINKER-MM1 trial in patients with relapsed/refractory multiple myeloma.
Sundar Jagannath, discusses the potential role for linvoseltamab in relapsed/refractory multiple myeloma.
April 24th 2024
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the design of the phase 3 CARTITUDE-4 trial in multiple myeloma.